David Evans, Ph.D.
About David Evans, Ph.D.
David Evans, Ph.D., serves as the Chief Scientific Officer at Sirnaomics, Inc., where he leads the development of siRNA therapeutics targeting cancer and fibrosis. With over thirty years of experience in the biotechnology sector, he has held significant roles at various organizations, including ThermoFisher Scientific and TGEN, and has co-founded multiple companies in the field.
Current Role at Sirnaomics
David Evans, Ph.D. serves as the Chief Scientific Officer at Sirnaomics, Inc. since 2018. In this role, he leads the development of small interfering RNA (siRNA) therapeutics targeting cancer and fibrosis. He utilizes proprietary Polypeptide Nanoparticles for effective delivery of these therapeutics. His responsibilities include overseeing products in various stages of development, from early preclinical studies to Phase 2 clinical trials. He has played a key role in advancing the company's research and development initiatives.
Previous Experience in Biotechnology
David Evans has over thirty years of experience in the biotechnology and biopharmaceutical industry. He previously worked at ThermoFisher Scientific/Dharmacon products as Senior Director of RNAi Discovery and Therapeutic Services from 2006 to 2008. Before that, he served as Head of Drug Discovery at TGEN from 2003 to 2006 and as Head of High Throughput Screening at Serono Pharmaceuticals from 1996 to 2000. His extensive background includes managing research teams focused on drug discovery and development.
Entrepreneurial Ventures
David Evans is a serial entrepreneur and co-founded Sirnaomics, Inc. in 2008. He has founded several companies that focus on high throughput screening, functional genomics, RNAi technology, drug target identification, and therapeutic development. His entrepreneurial efforts have contributed to advancements in the field of RNAi technology and the establishment of innovative research initiatives.
Educational Background and Expertise
David Evans holds a Ph.D. and has developed expertise in oncology and RNAi technology. His academic and professional background has equipped him with the skills necessary to lead scientific research teams and drive early-stage drug development efforts. He has been recognized as a pioneer in RNAi technology development and has received multiple NIH SBIR grants for his contributions to the field.
Research and Development Contributions
At Sirnaomics, David Evans has been instrumental in developing targeted delivery agents based on Polypeptide Nanoparticle technology. He has led the company's antiviral and anticancer programs, overseeing the management of In Vitro Screening labs for the Frederick National Lab for Cancer Research. His contributions have significantly impacted the advancement of siRNA therapeutics and their applications in treating various diseases.